News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
261,712 Results
Type
Article (13946)
Company Profile (304)
Press Release (247462)
Section
Business (79356)
Career Advice (151)
Deals (13190)
Drug Delivery (34)
Drug Development (50328)
Employer Resources (31)
FDA (5682)
Job Trends (5116)
News (144134)
Policy (10018)
Tag
Academia (902)
Alliances (21525)
Alzheimer's disease (756)
Approvals (5661)
Artificial intelligence (68)
Bankruptcy (97)
Best Places to Work (4522)
Biotechnology (249)
Breast cancer (109)
Cancer (888)
Cardiovascular disease (71)
Career advice (132)
CAR-T (73)
Cell therapy (217)
Clinical research (40137)
Collaboration (308)
Compensation (128)
COVID-19 (1006)
C-suite (78)
Cystic fibrosis (66)
Data (983)
Diabetes (85)
Diagnostics (1207)
Drug discovery (56)
Earnings (29004)
Events (47193)
Executive appointments (247)
FDA (6047)
Funding (306)
Gene editing (63)
Gene therapy (163)
GLP-1 (310)
Government (1065)
Healthcare (6543)
Infectious disease (1043)
Inflammatory bowel disease (98)
IPO (7197)
Job creations (859)
Job search strategy (127)
Layoffs (188)
Legal (1375)
Lung cancer (130)
Lymphoma (62)
Manufacturing (86)
Medical device (2558)
Medtech (2559)
Mergers & acquisitions (6128)
Metabolic disorders (257)
Neuroscience (999)
NextGen Class of 2024 (2004)
Non-profit (847)
Northern California (1091)
Obesity (140)
Opinion (91)
Parkinson's disease (75)
Patents (61)
People (25103)
Phase I (14150)
Phase II (18664)
Phase III (11818)
Pipeline (367)
Postmarket research (851)
Preclinical (5971)
Radiopharmaceuticals (205)
Rare diseases (201)
Real estate (1409)
Regulatory (8281)
Research institute (931)
Southern California (976)
Startups (1964)
United States (8655)
Vaccines (164)
Weight loss (83)
Date
Last 7 days (364)
Last 30 days (1422)
Last 365 days (20528)
2024 (20440)
2023 (22413)
2022 (26822)
2021 (27805)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16923)
Australia (2856)
California (2474)
Canada (809)
China (203)
Colorado (91)
Connecticut (103)
Europe (36445)
Florida (271)
Georgia (71)
Illinois (153)
Indiana (61)
Kansas (55)
Maryland (330)
Massachusetts (1955)
Minnesota (101)
New Jersey (630)
New York (682)
North Carolina (419)
Northern California (1091)
Ohio (82)
Pennsylvania (474)
South America (207)
Southern California (976)
Texas (278)
Washington State (247)
261,712 Results for "rubius therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
Rubius Therapeutics Announces Strategic Update
Rubius Therapeutics, Inc. announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform.
September 13, 2022
·
9 min read
Genetown
Rubius Therapeutics to Provide Strategic Update
Rubius Therapeutics, Inc. (Nasdaq: RUBY) today announced that the Company plans to provide a strategic update and host an investor teleconference and webcast on Tuesday, September 13, 2022, at 7:30 a.m. EDT.
September 12, 2022
·
1 min read
Business
Rubius Therapeutics Cuts 84% of Workforce, Explores Sale and Merger Options
Rubius Therapeutics plans to initiate a large restructuring initiative, which includes laying off 84% of its staff and a possible sale, the company announced Wednesday.
November 3, 2022
·
2 min read
·
Mark Terry
Genetown
Rubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 11:15am EDT.
September 19, 2022
·
3 min read
Business
Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes
Rubius Therapeutics, Inc. announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process.
November 2, 2022
·
5 min read
After a Standout IPO and Series of Pivots, Rubius Closes its Doors
Rubius Therapeutics’ board of directors has approved a plan to liquidate and dissolve the company, the Massachusetts-based biotech announced in an SEC form 8-K filed Monday.
February 22, 2023
·
2 min read
·
Tristan Manalac
Business
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open.
July 26, 2022
·
1 min read
Business
Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors.
May 24, 2022
·
5 min read
Business
Rubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Rubius Therapeutics, Inc. (Nasdaq: RUBY), today reported second quarter 2022 financial results and provided a business update.
August 9, 2022
·
14 min read
Business
Rubius Returns to Starting Board, Dismisses 75% of Staff
Rubius is undertaking another restructuring focused on its Red Cell Therapeutics technology that will result in the termination of 75% of its staff and a return to a preclinical starting board.
September 13, 2022
·
3 min read
·
Alex Keown
1 of 26,172
Next
